Contego Medical recently announced that Mitchell Silver, an interventional cardiologist and vascular medicine specialist, has joined the team as chief medical officer (CMO).
A press release notes that Silver will play a pivotal role in shaping the company’s clinical strategy and advancing the portfolio of carotid and thrombectomy products.
“His medical leadership and strategic guidance will help guide clinical development, regulatory affairs, and commercialisation efforts for the upcoming launch of the Neuroguard IEP system carotid stent delivery catheter, Neuroguard IEP Direct transcarotid revascularisation system, and Excipio peripheral thrombectomy devices,” the release reads.
Silver brings extensive experience in cardiovascular and vascular medicine and specialises in managing arterial, venous, and lymphatic diseases. Before joining Contego Medical, he was at OhioHealth Heart and Vascular Physicians in Columbus, USA, where he was the director of the Center for Critical Limb Care and Endovascular Research. Silver founded the Cornwell Center for Cardiovascular and Diabetes Care at Ohio University.
His contributions to the field include over 100 peer-reviewed manuscripts and book chapters on carotid artery atherosclerosis, peripheral vascular disease, and venous thromboembolism. He has been a proponent of carotid artery stenting since the mid-1990s and contributed to research efforts to develop the first embolic protection device.
Ravish Sachar, Contego Medical’s CEO and founder, stated: “Dr Silver is a visionary in the cardiovascular space. He has been deeply involved in the treatment of carotid and peripheral vascular disease for many years, and his experience and dedication to advancing medical research prepared him to make a significant impact here. He is uniquely suited for the role of Contego’s CMO, and we are very excited and honoured that he will be joining Contego full-time.”
Over the past decade, Silver’s research focused on deep vein thrombosis (DVT) and pulmonary embolism (PE). He served as the national principal investigator (PI) for the FLAME study, the largest prospective study of interventional treatment in high-risk PE and co-principal investigator of CLEAR DVT, an international study on acute DVT management.
Silver’s collaboration with Contego Medical dates back to the company’s inception. He served on the company’s board in the early days. “Joining Contego brings my career full circle, and I am energised to join the team at this important time in the company’s trajectory,” he said.
